J.P. Morgan analyst Cory Kasimov maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $183.00. The company’s shares closed last Monday at $140.32, close to its 52-week low of $121.32.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 18.2% and a 54.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Allogene Therapeutics.
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $251.89, an 80.5% upside from current levels. In a report released today, Jefferies also maintained a Hold rating on the stock with a $230.00 price target.
Based on BioNTech SE’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.53 billion and net profit of $3.17 billion. In comparison, last year the company earned revenue of $345 million and had a net profit of $367 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
Read More on BNTX:
- J.P. Morgan Keeps Their Buy Rating on Zurich Insurance Group (ZFSVF)
- Mizuho Securities Thinks Arcus Biosciences’ Stock is Going to Recover
- Stephens Thinks Everbridge’s Stock is Going to Recover
- Stephens Sticks to Its Buy Rating for Genasys (GNSS)
- Adaptimmune Therapeutics (ADAP) Receives a Hold from SVB Securities